Last reviewed · How we verify
NCT05056519
The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine
Phase 1 trial testing Live Attenuated Influenza Vaccine in Influenza Prevention in 160 participants. Status unknown.
30 December 2021
Quick facts
| Lead sponsor | Changchun BCHT Biotechnology Co. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 160 |
| Start date | 20 September 2021 |
| Primary completion | 30 December 2021 |
| Estimated completion | 30 March 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Live Attenuated Influenza Vaccine — full drug profile →
- Live Attenuated Influenza Vaccine placebo
Conditions studied
- Influenza Prevention — all drugs for Influenza Prevention →
Sponsor
Changchun BCHT Biotechnology Co. — full company profile →
Who can join
Adults 3 to 59, any sex, with Influenza Prevention. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Live Attenuated freeze-dried Influenza Vaccine has been licensed for use in 2020 (Approval No.S20200002), the sponsor of this research submitted an new application for non freeze-dried Live Attenuated Influenza Vaccine in 2021. The main objective of phase Ⅰ trail is to evaluate the safety of LAVI(non freeze-dried). The secondary objective is to evaluate the immunogenicity of LAVI(non freeze-dried).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05056519
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Live Attenuated Influenza Vaccine
Trials testing the same drug.
- NCT06501963 — Revealing Protective Immunity to Influenza Using Systems Immunology · Phase 4 · completed
- NCT03101462 — Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years · Phase 4 · completed
Other recruiting trials for Influenza Prevention
Currently open trials in the same condition.
- NCT07111078 — Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults · Phase 1 · recruiting
- NCT06863142 — Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP · Phase 1 · recruiting
Other Changchun BCHT Biotechnology Co. trials
Trials by the same sponsor.
- NCT07492303 — A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults · Phase 1 · not yet recruiting
- NCT07500207 — A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell) · Phase 3 · enrolling by invitation
- NCT07349017 — A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant) · Phase 1 · not yet recruiting
- NCT06548139 — Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical T · Phase 2 · not yet recruiting
- NCT06360250 — Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoc · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05056519 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changchun BCHT Biotechnology Co.
- Last refreshed: 24 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05056519.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing